Press Release
Protagonist Announces Nomination of PN-477, an Oral and Injectable GLP-1R, GIPR, and GCGR Triple Agonist Peptide Development Candidate for Obesity
A novel oral peptide PN-477o with once-daily dosing, high potency and activation of glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic peptide (GIP), and glucagon (GCG) receptors Company will also develop a subcutaneous version, PN-477sc, as a once-weekly injection IND-enabling studies underway, with Phase I study initiation expected in 2Q26 Webcast and conference call to be held today at 4:30 pm ET Read More
Press Release
Code 118 Security Wallet Launches: Built to Block Skimmers and Slim Down Pockets in 2025
Engineered with aerospace-grade aluminum and carbon fiber, Code 118 combines RFID-blocking security, auto-eject card access, and minimalist everyday carry convenience into a durable wallet solution designed for digital-first lifestyles in 2025. Read More
Press Release
Blue Heron Health News Shares Natural Approach to Daily Joint Support Through Shelly Manning's Arthritis Strategy
The 21-day anti-inflammatory wellness program developed by Shelly Manning offers a science-backed, food-first solution for individuals seeking natural relief from arthritis, joint stiffness, and inflammation-without drugs, injections, or restrictive diets. Read More
Press Release
GoldMember Lift Emerges as 2025’s Breakthrough Male Performance Supplement Backed by 89,000 Reviews
Clinically Studied Formula Featuring Nitrosigine®, S7® Blend, and Trans-Resveratrol Supports Circulation, Stamina, and Daily Vitality for Men Seeking Natural Performance Enhancement in 2025 Read More
Press Release
Fluff Pillow Launches Adjustable Comfort for 2025 Sleep Wellness: The Neck-Pain Solution That’s Reshaping Bedtime
The new Fluff Pillow combines a breathable cotton shell, vegan microfiber "Fluff™" fill, and a customizable dual-core design to help relieve pressure, regulate temperature, and promote pain-free sleep across all positions-supporting 2025 wellness goals through sustainable rest. Read More
Press Release
Sarama Announces Well Supported Equity Placement Of A$2.7m To Fund Laverton Drilling Campaign
NOT FOR DISTRIBUTION OR RELEASE IN THE UNITED STATES Highlights Well supported Placement to raise A$2.7 million, reflecting strong support from new and existing institutional, professional, and sophisticated investors. Funds will be primarily used to launch major further exploration initiatives including a drilling program in Q3 CY25 at the recently acquired Cosmo Gold Project in the prolific Laverton Gold District of Western Australia. The drilling will test high-priority targets within the 45km of combined gold-in-soil trends, representing the first coordinated large-scale modern exploration on this belt-scale project. Sarama's fully funded arbitration claim remains on track, meeting key milestones in pursuit of damages stated at no less than US$120 million from the Government of Burkina Faso. The acquisition of Mt Venn is progressing, with one final condition precedent remaining. Upon completion, Sarama will have tenements covering c.1,000km2 in the Eastern Goldfields with underexplored tenements and trucking distance to nearby mills. The Powerhouse Group of Companies (ASX: PVL) supported the raising with Powerhouse Advisory Australia Pty Ltd acting as lead manager and its funds management division cornerstoning the Placement. Read More
Press Release
Hospitals at Cybersecurity Crossroads: Projected Medicaid Cuts Threaten 25% of U.S. Hospitals - Black Book Research
Funding Shortfalls Pressure Small and Rural Hospitals to Delay Essential Data Security Investments; Survey of 187 Small Hospital Leaders Highlights Growing IT Vulnerabilities Read More
Press Release
Proof-of-Concept Results Show Jaguar Health's Crofelemer Reduced Total Parenteral Nutrition in Third Intestinal Failure Orphan Disease Patient
As recently announced, initial proof-of-concept results from this ongoing investigator-initiated trial (IIT) show crofelemer reduced the required total parenteral nutrition in the first participating microvillus inclusion disease (MVID) patient by up to 27% and in the first participating short bowel syndrome patient by up to 12.5% The first two patients in this IIT were taken off crofelemer after 12 weeks of treatment for a period intended to last 30 days, per the study protocol, but were promptly placed back on daily crofelemer treatment because their symptoms worsened Company strategy: Seek business development partnerships for license to develop and commercialize Jaguar's intestinal failure products, resulting in non-dilutive funding for Jaguar Read More
Press Release
US MedTech Disruptor OIC International Expands Into Asia, Central, and South America With Affordable Trauma Innovation
OIC International brings modular trauma systems to underserved global markets, advancing surgical care through innovation, accessibility, and regional collaboration. Read More
Press Release
ALT5 Sigma Corporation's Crypto-as-a-Service Platform Enables Stablecoin Management, Integration, and Utility Across All Leading Blockchains
Regulated entities can streamline stablecoin operations - permissioned or permissionless - using ALT5 Sigma's Crypto-as-a-Service platform, fully compatible with proprietary and third-party assets. Read More
Press Release
Ainos Completes Stock Consolidation, Enters New Phase of Global Expansion and Technology Commercialization
Partners With ASE to Scale AI Nose Deployment and Set New Standard in Intelligent Sensing Achieves Strategic Inflection Point in 1H 2025 with Partnerships and Operational Breakthroughs Read More
Press Release
5E Advanced Materials Progresses Commercial Strategy with 14 Customers Successfully Qualified and Growing Pipeline
A highly reputable national and multinational customer base across eight market segments reinforces the quality of 5E's boric acid and reflects changing global supply-demand dynamics Read More
Press Release
MIRA Reports Up to 30% Weight Loss and Reversal of High-Calorie and Nicotine Cravings in an Animal Model of Obesity and Craving Using SKNY-1, a Drug Candidate Under Definitive Agreement for Acquisition
Oral therapy designed to minimize CNS side effects shows dual activity in weight loss and smoking cessation models without muscle loss Read More
Press Release
